



The Commonwealth of Massachusetts
Executive Office of Health and Human Services
Department of Public Health
Bureau of Health Care Safety and Quality
Medical Use of Marijuana Program
99 Chauncy Street, 11th Floor, Boston, MA 02111

CHARLES D. BAKER
Governor

KARYN E. POLITO
Lieutenant Governor

JAN 30 2018

MARYLOU SUDDERS
Secretary

MONICA BHAREL, MD, MPH
Commissioner

Tel: 617-860-5370
www.mass.gov/medicalmarijuana

MANAGEMENT AND OPERATIONS PROFILE
Request for a Certificate of Registration to
Operate a Registered Marijuana Dispensary

INSTRUCTIONS

This application form is to be completed by an entity that wishes to apply for a Certificate of Registration to operate a Registered Marijuana Dispensary ("RMD") in Massachusetts, and has been invited by the Department of Public Health ("Department") to submit a *Management and Operations Profile* ("applicant").

Once invited by the Department to submit a *Management and Operations Profile*, the applicant must submit the *Management and Operations Profile* within 45 days from the date of the invitation letter, or the applicant must submit a new *Application of Intent* and fee.

If invited by the Department to submit more than one *Management and Operations Profile*, the applicant must submit a separate *Management and Operations Profile*, attachments, and application fee for each proposed RMD. Please identify each application of multiple applications by designating it as Application 1, 2 or 3 in the header of each application page. Please note that no executive, member, or any entity owned or controlled by such an executive or member, may directly or indirectly control more than three RMDs.

However, even if submitting a *Management and Operations Profile* for more than one RMD, an applicant need only submit one *Employment and Education Form*, *Character and Competency Form* and background check packet, including authorization forms for all required individuals and entities, and fee associated with the background checks.

Unless indicated otherwise, all responses must be typed into the application forms. Handwritten responses will not be accepted. Please note that character limits include spaces.

Attachments should be labeled or marked so as to identify the question to which it relates.

Each submitted application must be a complete, collated response, printed single-sided on 8 1/2" x 11" paper, and secured with a binder clip (no ring binders, spiral binding, staples, or folders).

Application ' of ' of 1

Applicant Corporation

Solar Therapeutics

Mail or hand-deliver the *Management and Operations Profile*, with all required attachments, the \$30,000 application fee, and completed Remittance Form to:

Department of Public Health
Medical Use of Marijuana Program
RMD Applications
99 Chauncy Street, 11th Floor
Boston, MA 02111

All fees are non-refundable and non-transferable.

REVIEW

Applications are reviewed in the order they are received.

After a completed application packet and fee is received by the Department, the Department will review the information and will contact the applicant if clarifications or updates to the submitted application materials are needed. The Department will notify the applicant whether it has met the standards necessary to be invited to submit a *Siting Profile*.

Applicants must receive an invitation from the Department to submit a *Siting Profile* within 1 year of the date of submission of the *Management and Operations Profile*, or the applicant must submit a new *Application of Intent* and fee in order to proceed in the application process.

PROVISIONAL CERTIFICATE OF REGISTRATION

Applicants must receive a Provisional Certificate of Registration from the Department within 1 year of the date of the invitation letter from the Department to submit a *Siting Profile*. If the applicant does not meet this deadline, the application will be considered to have expired. Should the applicant wish to proceed with obtaining a Certificate of Registration, a new application must be submitted, beginning with an *Application of Intent*, together with the associated fee.

REGULATIONS

For complete information regarding registration of an RMD, please refer to 105 CMR 725.100, as well as materials posted on the Medical Use of Marijuana Program website: www.mass.gov/medicalmarijuana.

It is the applicant's responsibility to ensure that all responses are consistent with the requirements of 105 CMR 725.000, et seq., and any requirements specified by the Department, as applicable.

PUBLIC RECORDS

Please note that all application responses, including all attachments, will be subject to release pursuant to a public records request, as redacted pursuant to the requirements at M.G.L. c. 4, § 7(26).

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: EFD

Application 1 of 1

Applicant Corporation

Solar Therapeutics

QUESTIONS

If additional information is needed regarding the RMD application process, please contact the Medical Use of Marijuana Program at 617-660-5370 or RMDapplication@state.ma.us.

CHECKLIST

The forms and documents listed below must accompany each application, and be submitted as outlined above:

- ☒ A fully and properly completed *Management and Operations Profile*, signed by an authorized signatory of the applicant
- ☒ A completed *Remittance Form* (use template provided)
- ☒ A bank or cashier's check made payable to the *Commonwealth of Massachusetts* for \$30,000
- ☒ A copy of the applicant's *Articles of Organization* (as outlined in Section B)
- ☒ A copy of the applicant's *Certificate of Good Standing* (as outlined in Section B)
- ☒ A copy of the applicant's bylaws or operating agreement (as outlined in Section B)
- ☒ An *Employment and Education Form* for each required individual (as outlined in Section D)
- ☒ A completed and signed *Character and Competency Form* for each required actor (as outlined in Section G)
- ☒ A sealed envelope with the name of the applicant and marked "authorization forms," that contains the background check authorization forms (use forms provided) and fee, for each of the following actors:

The Chief Executive Officer; Chief Operating Officer; Chief Financial Officer; individual/entity responsible for marijuana for medical use cultivation operations; individual/entity responsible for the RMD security plan and security operations; each individual performing onsite services on behalf of a consulting or contracted company as Cultivation or Security Manager or the equivalent, if known during the application process; each member of the Board of Directors; each Member of the Corporation, if any; and each person and entity known to date that is committed to contributing 5% or more of initial capital to operate the proposed RMD. If the applicant does not have a Chief Executive Officer, Chief Operating Officer, or Chief Financial Officer, it must identify the individuals performing the equivalent duties for the applicant and submit these forms for each said individual.

For entities contributing 5% or more of initial capital to operate the proposed RMD, the forms must be completed by the entity's Chief Executive Officer or Executive Director and President or Chair of the Board of Directors. If the entity does not have a Chief Executive Officer or Executive Director or President or Chair of the Board of Directors, it must identify the individuals performing the equivalent duties for the entity and submit these forms for each said individual.

SECTION A. APPLICANT INFORMATION

1. Solar Therapeutics, Inc.
Legal name of Applicant Corporation
2. Edward Dow III
Name of Applicant Corporation's Chief Executive Officer
3. 2 Seaport Lane, c/o Vicente Sederberg LLC, Boston, MA 02210
Mailing address of Applicant Corporation (Street, City/Town, Zip Code)
4. Edward Dow III
Applicant Corporation's point of contact (name of person Department should contact regarding this application)
5. (603) 498-6326
Point of contact's telephone number
6. Edward.dow.iii@gmail.com
Point of contact's e-mail address
7. Number of applications: How many *Management and Operations Profiles* does the applicant intend to submit?

1**SECTION B. INCORPORATION**

8. Attach a copy of the applicant's *Articles of Organization*, documenting that the applicant is an entity incorporated in Massachusetts.
9. Attach a copy of the applicant's *Certificate of Good Standing* from the Massachusetts Secretary of the Commonwealth. The *Certificate of Good Standing* must be dated no earlier than 90 days prior to the date the *Management and Operations Profile* is received by the Department.
10. Attach a copy of the applicant's bylaws (if a non-profit or domestic business corporation) or operating agreement (if a limited liability company).

SECTION C. NON-PROFIT COMPLIANCE

If the applicant is a non-profit corporation, answer each of the questions in Section C to explain how the corporation will remain in compliance with the non-profit requirements of Ch. 369 of the Acts of 2012, the regulations at 105 CMR 725.000, and "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance." Please refer to the "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance" document in completing this Section.

11. Please identify any management company that the applicant intends to utilize and summarize the terms of any agreement or contract, executed or proposed, with the management company.

Solar Therapeutics, Inc. ("Solar Therapeutics") has not engaged any management company, and there are no agreements or contracts, executed or proposed, with any management company. Solar Therapeutics is in compliance with the non-profit requirements of Ch. 369 of the Acts of 2012, the regulations at 105 CMR 725.000 et seq., and the "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance."

12. Please identify any agreements or contracts, executed or proposed, in which the applicant will engage in a Related Party Transaction and summarize the terms of each such agreement.

Edward Dow is the President and CEO of Dow Capital Partners LLC, which is a capital contributor of greater than 5% for Application 1 of 1. It is expected that Solar Therapeutics will execute a loan agreement with Dow Capital Partners LLC for all funds provided to the RMD. While the terms have not been finalized, the interest rate will not exceed 18% per annum.

Once Solar Therapeutics has executed a loan agreement with Dow Capital Partners LLC, Solar Therapeutics will provide a copy of the agreement to the DPH along with an independent legal opinion to ensure that any Related Party Transaction complies with the non-profit requirements of Ch. 369 of the Acts of 2012, the regulations at 105 CMR 725.00, and the DPH's "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance." Solar Therapeutics understands that any such agreement and its respective independent legal opinion must be submitted to the DPH prior to receiving PCR.

13. Please identify whether any members of the Board of Directors are also serving as employees of the proposed RMD and, if so, their title and role with the proposed RMD.

Edward Dow, President/Director of the Board of Directors & CEO/COO/CFO

As CEO, Edward will be the executive ultimately responsible for Solar Therapeutic's overall operations, performance, patient service, and compliance with 105 CMR 725. He will be the leader of the company and will serve as the main link between the Company's Board of Directors and Solar Therapeutics's various operational departments.

As COO, Edward will also be responsible for overseeing the day-to-day operations of Solar Therapeutics, establishing procedures and processes for each department, and providing timely operational information to Solar Therapeutics's executive management team.

As CFO, Edward will further be responsible for the overall financial stability and financial and reporting compliance of Solar Therapeutics. Edward will oversee all accounting functions, including preparing budgets and financial statements, monitoring expenditure and liquidity, and reporting financial performance to Solar Therapeutics's Board of Directors and executive management team.

14. Please identify whether any members of the Board of Directors are serving as officials, executives, corporate members or board members for any management company, investor or other third party proposed to contract or otherwise conduct business with the proposed RMD.

Edward Dow is the President and CEO of Dow Capital Partners LLC, which is a capital contributor of greater than 5% for Application 1 of 1. It is expected that Solar Therapeutics will execute a loan agreement with Dow Capital Partners LLC for all funds provided to the RMD. While the terms have not been finalized, the interest rate will not exceed 18% per annum.

Once Solar Therapeutics has executed a loan agreement with Dow Capital Partners LLC, Solar Therapeutics will provide a copy of the agreement to the DPH along with an independent legal opinion to ensure that any Related Party Transaction complies with the non-profit requirements of Ch. 369 of the Acts of 2012, the regulations at 105 CMR 725.00, and the DPH's "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance." Solar Therapeutics understands that any such agreement and its respective independent legal opinion must be submitted to the DPH prior to receiving PCR.

Application 1 of 1

Applicant Corporation

Solar Therapeutics

15. Please identify any contract or agreement, executed or proposed, under which a percentage or portion of the applicant's revenue will be distributed to a third party and summarize the terms of any such agreement or contract.

Solar Therapeutics does not have any contract, executed or proposed, under which a percentage or portion of Solar Therapeutics's revenue will be distributed to a third party. Solar Therapeutics understands that the sharing of revenue is inconsistent with the non-profit objective of using revenue solely in furtherance of Solar Therapeutics's non-profit purpose as required by 105 CMR 725.100(A)(1).

ATTESTATION

The applicant agrees and attests that it will operate in compliance with the "Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance."



Signature of Authorized Signatory

1/17/2018

Date Signed

Edward F Dow III

Print Name of Authorized Signatory

CEO

Title of Authorized Signatory

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: EFD

SECTION D. EXPERIENCE

16. Attach a completed and signed *Employment and Education Form* (use template provided) for each required individual (as outlined in the *Employment and Education Form*)
17. Describe the experience, and length of experience, of the applicant's Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, or their equivalent, with running a business.

Edward Dow (CEO/COO/CFO) is an entrepreneur with more than 5 years of experience running a business. Edward is the founder and President of Bay State Metal Finishing Corporation, which provides engineered metal finishes to the oceanography, aeronautics, and automated machining industries in the United States. Formerly, he spent 3 years working for Woods Hole Oceanographic Institution (WHOI), a large non-profit research organization on Cape Cod, where he managed engineering projects, including a cost-center and build schedule for specific commercial instruments.

Application 1 of 1

Applicant Corporation

Solar Therapeutics

18. Describe the experience, and length of experience, of the application's Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, or their equivalent, with providing health care services.

Edward Dow (CEO/COO/CFO) has no direct experience providing health care services.

19. Describe the experience, and length of experience, of the applicant's Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer, or their equivalent, with providing services for marijuana for medical purposes.

Edward Dow (CEO/COO/CFO) has no direct experience providing services for marijuana for medical purposes. However, Edward has over 8 years of project management experience where he dealt regularly with both state and federal regulatory authorities in the course of carrying out his duties, demonstrating a clear ability to meet the complicated compliance obligations inherent to providing services for marijuana for medical purposes.

20. Describe the experience, and length of experience, of the applicant's individual/entity responsible for marijuana for medical use cultivation operations and individual/entity responsible for the RMD security plan and security operations with providing services for marijuana for medical purposes.

Colleen Kanaley Dow, the individual responsible for marijuana for medical use cultivation operations, has no direct experience with providing services for marijuana for medical purposes. However, Colleen has over 10 years of experience in the commercial horticulture and gardening industry, holding an Associate's Degree and a Horticulture Certificate from Cape Cod Community College.

Kevin Traver, the individual responsible for the RMD security plan and security operations, has no direct experience with providing services for marijuana for medical purposes. However, Kevin is a security professional with a background in physical security operations and the development and implementation of security training programs. He has 17 years of experience in operational security. Kevin also has 15 years of experience in the nuclear security industry where he worked as the Lead Controller and Lead Adversary Controller for Pilgrim Station, the Lead Adversary Controller for River Bend Station, and worked as the Lead Adversary Controller for River Bend Station. While working in nuclear security training, Kevin was responsible for the overall command and control of force and adversary teams on force exercises. He also has 5 years of experience as an alarm station operator, 3 years of experience as a response team leader, 10 years of experience as a security instructor with over 9,000 hours of classroom/range instruction time, and 9 years of experience using a systematic approach to training. Kevin also has over 500 hours conducted as a member of a root cause inspection or pre-inspection readiness team. He is also currently enrolled in a program to become a certified security specialist from Executive Security International in Denver, CO, with a projected graduation date of May 2018.

SECTION E. OPERATIONS

21. Provide a summary of the applicant's operating procedures for the cultivation of marijuana for medical use.

Solar Therapeutics's marijuana cultivation SOPs are intended to ensure agent, product & public safety; produce consistent, predictable yields based on accepted science; and create transparent, compliant & efficient operations. Our extensive SOPs address cultivation topics include, but are not limited to: CO2 Systems; Crop/Supply Management; Disease Management; Environmental Controls; Pest Management; Fertilizer/Soil/Media Management; Spray/Feeding Protocols; Nutrient Prep Form; Hygiene/Sanitation; Infected Handler Guidelines; Security/Limited Access Areas; Monitoring/Record keeping; Inventory Management/Storage; Procedure Variances; Quality Assurance; & Water Quality.

No non-organic pesticides will be used, and cultivation will be consistent with DPH guidance on U.S. DOA 7 CFR, Part 205 organic requirements. Our cultivation process will use best practices to prevent contamination, including, but not limited to mold, fungus, bacterial diseases, rot, pests, non-organic pesticides, mildew, & other contaminants identified as posing potential harm. The soil used for cultivation will meet the U.S. Agency for Toxic Substances & Disease Registry's Environmental Media Evaluation Guidelines for residential soil levels. Waste disposed of to minimize odor/pests.

Pursuant to 725.105(B)(1)(c)-(f), all phases of cultivation (strain selection, seed germination, grow mediums and organic nutrient selection, establishment of lighting grow cycle, harvesting, drying, & curing) will take place in designated, locked, limited access areas that are monitored by a surveillance system compliant with 725.110(D)(1)(d)-(i). All of our source soils/solids will be sampled/analyzed prior to use, when new soils/solids are received from a different source, & annually.

Proper sampling collection steps will be followed including use of disposable gloves, clean sampling area, appropriate tools & containers, no cross contamination & time records kept for each sample. Representative samples will be collected and maintained for DPH review with duplicate samples collected at least annually & 1 for every 20 samples. All logbooks & chain of custody forms will be available for DPH review. We will create & maintain cultivation and sampling diagrams for review. We will have a sufficient plumbing system & water supply & our water will be derived from a public source & public records of analysis will be maintained & available for DPH review.

Best Management Practice, Good Agricultural Practice, & Good Handling Practice will be used. Solar Therapeutics has adopted marijuana cultivation standards from the American Herbal Pharmacopoeia & the American Herbal Products Association & adapted USDA Organic Standards & FDA standards to create a holistic medical marijuana crop management system. We also have adopted or adapted the use of the HACCP Principles & Application Guidelines (National Advisory Committee on Microbiological Criteria for Foods).

22. Describe the types and forms of Marijuana Infused Products ("MIPs") that the applicant intends to produce, if any.

Solar Therapeutics will produce high-quality MIPs & comply with Regs. MIPs will be medicinal in nature, lab tested & packaged in dosage levels allowing patients to self-titrate. At minimum, product line will include: transdermal/topical salve and patches, creams/lotions, oral mucosal/sublingual dissolving tablets, tinctures, sprays, inhalation-ready-to-use CO2 extracted hash oils, pre-dosed oil vaporizers, ingestion-capsules, food/oil/beverages.

MIPS will have a legible, affixed label w/ letters at least 1/16" in size and info required by 725.105(E)(3), will not resemble commercially available candy & be packaged in plain/opaque tamper/child-proof containers w/o depictions except Solar Therapeutics logo. Accidental ingestion of edibles/beverages to be avoided via proper packaging & labeling. MIPS produced are not considered a food/drug per M.G.L. c94, s.1.

Marijuana (excluding MIPS) products will be properly, legibly and firmly labeled per 725.105(E)(2). All products will be weighed with a certified Class II NTEP Balance.

Ingredients and cannabinoid profiles will be on labels. Food additives will be approved/properly used. 3rd party sample results to calculate extract addition quantities for exact dosage & consistent results.

23. Provide a summary of the applicant's methods of producing MIPs, if the applicant intends to produce MIPs.

Solar Therapeutics will create MIPs to treat a range of debilitating conditions.

Ingredients from approved source will be safe, unadulterated & labeled. Agents wear gloves & utilize ware washing facilities in kitchen w/o pests. Surfaces, utensils, equipment & linens properly sanitized, stored, dried & handled to prevent contamination during preparation, storage & display.

Proper cooling methods to prevent microorganism growth; approved thawing methods & accurate thermometers. Prepared on food-grade stainless steel tables & packaged in secure area with security cameras. MIPS tested pursuant to 725.105(C)(2) & HACCP compliant. TPHC used if appropriate.

Leaves & flowers of female plants processed in safe/sanitary manner, well cured & free of seeds, stems, dirt, sand, debris & other foreign matter; and free of contamination by mold, rot, fungus & bacterial disease.

Extraction/Refining: prep w/ lab quality grinder; oil (butter/olive oil), ethanol and/or supercritical CO2 extraction; external testing for cannabinoid profile & potency; decarboxylation. If practicable fractioning to produce pure active cannabinoids; fracture, separate & purify to produce concentrates that are high in specific, single cannabinoids using HPLC.

29. Provide a summary of the applicant's operating procedures for quality control and testing of product for potential contaminants.

Solar Therapeutics's SOPs comply with DPH Regs and protocols for quality control/testing.

All sampling:

- Decontaminated area
- Proper tools & disposable gloves
- Separate & store in appropriate container; no cross contamination
- Use Chain of Custody form
- Records kept > 1yr

Finished MJ:

- Sample from 5% of finished MJ
- Collection plan for each product type produced
- Log-collection date/time; agent IDs; product type & procedure (grinding, mixing); sample ID'd by batch#, ID#, batch impacted
- Labels=batch/sample ID#+date/time of collection & agent ID

Grow Media:

- Source soils & solids prior to use, when changed, not less than 1X/ 6 mo. w/ duplicates every 20X
- Media lots tracked to plants used with and logged per DPH Regs.
- Non-PWS: sampled prior to use & quarterly; PWS: records maintained & avail.

Testing:

Completed post sampling by DPH approved independent ISO 17025 lab. Tested for cannabinoid profile and contaminants (mold, mildew, heavy metals, plant-growth regulators, non-organic pesticides, & info DPH requires). Excess MJ from lab destroyed. Lab to provide signed narrative detailing:

- Sample
- Analysis
- Methods
- Chain of custody docs
- Info sought
- Summary & detail of results incl. units of measure, date/time

Results kept > 1yr; how destruction of product, investigation of source of contamination & mitigation steps. No Solar Therapeutics agent will have financial interest in lab. No lab employee will get compensation from RMD. Lab employees to be registered agents.

30. Provide a summary of the applicant's operating procedures for maintaining confidentiality of registered qualifying patients, personal caregivers, and dispensary agents, as required by law.

In compliance with 105 CMR 725.200, 725.105(H)&(I), patients, caregivers, & agent info is confidential & shall not be disclosed without the written consent of the individual to whom the information applies, or as required under or court order. DPH may access this information to carry out official duties. Hard copies of records stored in secure locked area, w/ limited access. Any loss/alteration of records related to MJ/MIPS, patients, caregivers, or agents reported to DPH, law enforcement & protected party.

Agents will have documented mandatory confidentiality training.

Patient tracking software will be in accordance with HIPAA principles & encrypted. Network servers will be protected by SSL, firewall, biometric locks in a secure area with 24hr surveillance. Software & infrastructure will be updated regularly, including relevant security patches. Software will be compliant & compatible with DPH's electronic system. Access to database limited to key agents.

Data security strategies incl. frequent password changes, length & character diversity requirements for passwords, restrictions of personal flash/thumb drives on computers, marking software for each system and securing when not in use.

Emails to patients will say "Confidential" & be sent on secure servers, either individually, using BCC, or using secure bulk email and will not provide patient info or refer to MJ in subject line.

Depending on siting & balanced with security, parking, entrance & exit will be discreet.

31. Provide a summary of the applicant's personnel policies.

Solar Therapeutics is in compliance w/ 105 CMR 725.105(I)(4) & committed to safety, professional development, compliance, equitable compensation & healthcare benefits. Solar Therapeutics to register in the MMJ Online System- BOD/agents/EMTs/volunteers will be RMD agents & remain compliant per 725.030(A)-(C) & (E). Personnel records will be kept for at least 1yr following termination. RMD to notify DPH no more than 1 business day after termination.

To strengthen local community, recruiting locally is priority. Agents will receive training on confidentiality, internal security policies, emergency procedures and will complete training specific to their job function. Agents will receive min. 8hrs of on-going training annually.

Any agent who diverts MJ or engages in unsafe practices will be dismissed and such activities will be reported to law enforcement & DPH.

Agents in contact with MJ or non-edible MIPS, will be subject to the requirements for food handlers specified in 105 CMR 300.000 & shall conform to sanitary & good hygienic practices.

Solar Therapeutics provides equal opportunities regardless of race, religion, ethnicity, sexual orientation or other discrimination factors. Policies include: safety, harassment, work hours, job reviews, maintaining alcohol, tobacco, & drug free workplace, compensation, benefits, vacation/holidays/leaves, training/professional development, record keeping, agent registration, compliance, security, standards of conduct, confidentiality.

33. Provide a summary of the applicant's operating procedures for record keeping.

Solar Therapeutics's SOPs ensure records are accurate & compliant with 105 CMR 725.105(G)-(I). Records maintained & avail. upon request include, but not limited to:

- Inventory
- Sales/Seed-to-Sale Tracking/Cultivation Records- incl. ID of buyer, quantity, form, price & inventory records per Regs
- Personnel Records-incl. staffing plan/org charts/job descriptions/training materials; list of non-profit BOD&EMT; records for agents kept for >1 yr. after termination incl. agent registration/de-registration notification, age, crim. history incl. CORI (separate from others); agents' written acknowledgment of limitations on cultivate/harvest/prepare/package/transport/dispense authority; attestation that agent will not divert; DPH ID card; agent application fee; yearly renewal of DPH ID; changes to submitted info; salaries/wages/stipends/compensation/bonuses/benefits to anyone associated with the RMD
- Business Records-assets & liabilities; monetary transactions; account info incl. journals/ledgers/agreements/checks/invoices/vouchers; 3rd party financial audits
- Training Records
- Patient Ed. Materials
- Waste Disposal &Transportation
- Product Testing
- Security
- Recalls/Withdrawals/Complaints
- Incident Reports-immediately notify PD & DPH w/in 24hrs of discovering loss/unauthorized alteration of records
- SOPs/Changes to SOPs
- DPH correspondence

Records kept in secure location per DPH Regs. After closure, records kept min of 2yrs at RMD's expense in form/location acceptable to DPH.

34. Provide a summary of the applicant's plans for providing patient education.

Pursuant to 725.105(K), Solar Therapeutics will have an adequate supply of up-to-date educational materials for patients & caregivers. Materials will be available in languages accessible to all of patients & caregivers, including for the visually- and hearing-impaired.

In addition to patient consultation/education, RMD will hold educational meetings. Education materials include, but are not limited to:

- Warnings: FDA has not analyzed or approved marijuana; there is limited information on side effects; potential health risks; marijuana should be kept away from children; driving under the influence of marijuana is prohibited by M.G.L. c. 90, s. 24; machinery should not be operated
- Info to assist in selection, descriptions of the differing effects of strains, as well as the various forms & routes of administration
- Patient Log: to track the strains used & their associated effects
- Dosage Guidelines: proper dosage & titration for each route of administration; emphasis on using the smallest amount possible to achieve the desired effect; impact of potency explained
- Info regarding tolerance, dependence & withdrawal
- Substance abuse signs & symptoms & referral info for treatment programs
- Statement that patients may not distribute marijuana to other individuals & that unused, excess, or contaminated product must be returned to RMD for disposal
- Patient rights
- Condition-specific booklets
- Any other info required by DPH

All materials will be made available to DPH upon request.

36. Provide a summary of the applicant's policies and procedures for the provision of marijuana for medical use to registered qualifying patients with verified financial hardship without charge or at less than the market price.

Solar Therapeutics is committed to assisting those with verified financial hardships (VFH). Patients will be considered to have a VFH if they are a recipient of MassHealth or Supplemental Security Income, or their household income does not exceed 300% of the federal poverty level, adjusted for family size.

All patients with a documented VFH as defined by 105 CMR 725.004 will be provided reduced cost or free marijuana.

Solar Therapeutics will provide patients with a VFH affidavit form to determine whether a patient qualifies for a VFH per 105 CMR 725.004 and 105 CMR 725.100(A)(6).

The form will request that patients provide proof of a VFH by submitting a copy of one of the following:

- Official MassHealth card issued by the Commonwealth;
- Supplemental Security Income benefit verification letter;
- State or Federal tax return from current or previous year; or
- Supplemental Nutrition Assistance Program (SNAP) statement from the current year.

Based on current projections, Solar Therapeutics plans to provide free or low cost medicine at the following levels:

- ≤100% of FPL: free up to 1 gram/week, 25% discount thereafter up to 1 ounce/month. Paraphernalia at cost;
- >100% but ≤200% of FPL: free up to .5 gram/week, 15% discount thereafter up to 1 ounce/month. Paraphernalia at cost + 10%;
- >200% but ≤300% of FPL: 5% discount on up to .5 ounce/month. Paraphernalia at cost + 20%; and
- >300% of FPL: TBD on a case by case basis.

37. Provide a summary of the training(s) that the applicant intends to provide to Dispensary Agents.

Solar Therapeutics has identified areas of training required for all agents to perform job duties and functions safely and in compliance with all applicable laws and regulations. Training programs will be tailored to the roles and responsibilities of the job function of each dispensary agent. Dispensary agents must complete training prior to performing job functions. At a minimum, 8 hours of on-going training will be required annually. All training records will include a signed statement of the agent indicating the date, time, and place they received training and the topics discussed, including the name and title of presenters.

Training, depending on agent position, will include:

- New agent orientation; Overview of the Act for Humanitarian Use of Medical Marijuana & 105 CMR 725.000
- Smoke, alcohol & drug free workplace
- Storage
- Patient & caregiver identification
- Compliance, regulation, & law
- Privacy & Confidentiality
- Cultivation & MIPs processing, safety, & security
- Dispensary safety & security & LAAs
- Emergency & incident management
- Inventory management & diversion prevention
- Manufacturing safety & security
- Waste disposal
- Community & patient interaction
- Record keeping & reporting
- Product handling & sanitation
- Transportation
- Advertising restrictions
- Whistleblowing
- Law enforcement interaction
- Internal audits
- Patients w/disabilities
- Testing/sampling
- Dispensing limits
- Packaging/labeling

Our SOPs also detail training evaluations & performance reviews.

38. Will the applicant provide worker's compensation coverage to its Dispensary Agents?

Yes ☒ No ☐

39. Will the applicant obtain professional and commercial insurance coverage?

Yes ☒ No ☐

40. Describe the applicant's plan to obtain liability insurance or place in escrow the required amount to be expended for the coverage of liabilities.

Solar Therapeutics will contract w/ insurance provider to maintain general liability insurance coverage: no less than \$1,000,000/occurrence & \$2,000,000 in aggregate annually; product liability coverage for no less than \$1,000,000/occurrence & \$2,000,000 in aggregate annually. Deductible no higher than \$5,000/occurrence.

If adequate coverage unavailable, at least \$250,000 will be placed in escrow to be expended for coverage of liabilities. Any withdrawal from escrow to be replenished w/in 10 business days and will carry automobile coverage, as well as property and casualty coverage. Replacement cost will be used to value all property ensuring a full recovery in event of a catastrophe. Business interruption coverage allows RMD to continue paying employees, vendors, taxes, & fees during reconstruction and also provides capital for any emergency inventory purchases from another RMD.

Solar Therapeutics will carry personal & advertising injury insurance, as well as employment practice liability coverage for directors & officers. Staff that transports cash or medical MJ/MIPs will be bonded. RMD will consider additional coverage based on availability & cost-benefit analysis and will keep reports documenting compliance with 725.105(Q).

SECTION F. CAPITAL CONTRIBUTORS

List all persons and entities known to date that are committed to contributing 5% or more of initial capital to operate the proposed RMD. For entities contributing initial capital to operate the proposed RMD, list the entity's Chief Executive Officer or Executive Director and President or Chair of the Board of Directors, or their equivalent.

Attach additional tables if needed.

Individual Name	Amount of Initial Capital Committed	% of Initial Capital Committed
	\$	
	\$	
	\$	
	\$	
	\$	

Entity Name	Leadership Names	Amount of Initial Capital Committed	% of Initial Capital Committed
Dow Capital Partners LLC	Edward Dow III (CEO) Entity CEO or ED	\$ 500,000.00	100
	Edward Dow III (President) Entity Pres or Chair		
	Entity CEO or ED	\$	
	Entity Pres or Chair		
	Entity CEO or ED	\$	
	Entity Pres or Chair		

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: EFD

SECTION G. CHARACTER AND COMPETENCY FORMS

41. Attach a completed and signed *Character and Competency Form* (use templates provided) for each required actor (as outlined in the *Character and Competency Forms*). Please note that there is a “Form for an Individual” and a “Form for an Entity.”

Application 1 of 1

Applicant Corporation
ATTESTATIONS

Solar Therapeutics

Signed under the pains and penalties of perjury, I, the authorized signatory of the applicant, agree and attest that all information included in this application is complete and accurate and that I have an ongoing obligation to submit updated information to the Department if the information presented within this application has changed.



Signature of Authorized Signatory

1/17/2018

Date Signed

Edward Dow III

Print Name of Authorized Signatory

CEO

Title of Authorized Signatory

The applicant agrees and attests that it will operate in compliance with all applicable state laws and regulations, including, but not limited to, laws regarding child support and taxation.



Signature of Authorized Signatory

1/17/2018

Date Signed

Edward Dow III

Print Name of Authorized Signatory

CEO

Title of Authorized Signatory

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: EFD

Application 1 of 1

Applicant Corporation

Solar Therapeutics

I, the authorized signatory for the applicant, hereby attest that if the applicant is allowed to proceed to submit a *Siting Profile*, the applicant is prepared to comply with all *Siting Profile* requirements.



Signature of Authorized Signatory

1/17/2018


Date Signed

Edward Dow III

Print Name of Authorized Signatory

CEO

Title of Authorized Signatory



The Commonwealth of Massachusetts
William Francis Galvin

Minimum Fee: \$35.00

Secretary of the Commonwealth, Corporations Division
One Ashburton Place, 17th floor
Boston, MA 02108-1512
Telephone: (617) 727-9640

Articles of Organization

(General Laws, Chapter 180)

Identification Number: 001302432

ARTICLE I

The exact name of the corporation is:

SOLAR THERAPEUTICS INC.

ARTICLE II

The purpose of the corporation is to engage in the following business activities:

THE CORPORATION IS ORGANIZED AND AT ALL TIMES SHALL BE OPERATED EXCLUSIVELY FOR CHARITABLE, SCIENTIFIC, CIVIC, RELIGIOUS, LITERARY, OR EDUCATIONAL PURPOSES PURSUANT TO MGL CHAPTER 180 § 4.

ARTICLE III

A corporation may have one or more classes of members. If it does, the designation of such classes, the manner of election or appointments, the duration of membership and the qualifications and rights, including voting rights, of the members of each class, may be set forth in the by-laws of the corporation or may be set forth below:

ARTICLE IV

Other lawful provisions, if any, for the conduct and regulation of the business and affairs of the corporation, for its voluntary dissolution, or for limiting, defining, or regulating the powers of the corporation, or of its directors or members, or of any class of members, are as follows:

(If there are no provisions state "NONE")

THE CORPORATION IS ORGANIZED SOLELY FOR THE FURTHERANCE OF ITS NONPROFIT PURPOSES. THE NET EARNINGS OF THE NONPROFIT SHALL NOT INURE TO THE BENEFIT OF ITS MEMBERS, DIRECTORS, OFFICERS, OR OTHER PRIVATE PERSON OR BE DISTRIBUTABLE TO HERETO; HOWEVER, REASONABLE COMPENSATION MAY BE PAID, AT THE AUTHORITY OF THE CORPORATION, FOR SERVICES RENDERED AND PAYMENTS AND DISTRIBUTIONS MAY BE EXECUTED IN FURTHERANCE OF THE NONPROFIT PURPOSES OF THE CORPORATION. IN ACCORDANCE WITH THE STATUTES OF THE COMMONWEALTH OF MASSACHUSETTS, THE BOARD OF DIRECTORS SHALL DISPOSE OF ALL THE ASSETS OF THE CORPORATION EXCLUSIVELY FOR THE PURPOSE OF THE CORPORATION, AFTER PAYING OR MAKING PROVISIONS FOR THE PAYMENT OF ALL OF THE LIABILITIES OF THE CORPORATION, IN THE EVENT OF THE DISSOLUTION OF THE CORPORATION, AS THE BOARD OF DIRECTORS SHALL DETERMINE. THE CORPORATION'S OFFICERS AND DIRECTORS SHALL NOT BE PERSONALLY LIABLE TO THE CORPORATION FOR MONETARY DAMAGES FOR A BREACH OF FIDUCIARY DUTY, OR ARISING THEREOF, AS AN OFFICER OR DIRECTOR NOTWITHSTANDING ANY PROVISION

OF LAW IMPOSING SUCH LIABILITY. HOWEVER, TO THE EXTENT THAT APPLICABLE LAW IMPOSES LIABILITY, THE FOREGOING SHALL NOT ELIMINATE OR LIMIT THE LIABILITY OF AN OFFICER OR DIRECTOR (I) FOR A BREACH OF THE OFFICER'S OR DIRECTOR'S DUTY OF LOYALTY TO THE CORPORATION OR ITS MEMBERS, (II) FOR ACTS OR OMISSIONS NOT IN GOOD FAITH OR WHICH INVOLVE INTENTIONAL MISCONDUCT OR A KNOWING VIOLATION OF THE LAW, OR (III) FOR ANY TRANSACTION FROM WHICH THE OFFICER OR DIRECTOR DERIVED AN IMPROPER PERSONAL BENEFIT. TO THE EXTENT LEGALLY PERMISSIBLE, THE CORPORATION SHALL INDEMNIFY EACH PERSON WHO MAY SERVE OR WHO HAS SERVED - AT ANY TIME - AS AN OFFICER OR DIRECTOR OF THE CORPORATION AGAINST ALL EXPENSES AND LIABILITIES WITHOUT LIMITATION, WHICH SHALL INCLUDE, INTER ALIA, COUNSEL FEES, JUDGMENTS, FINES, EXCISE TAXES, PENALTIES AND SETTLEMENT PAYMENTS, REASONABLY INCURRED BY OR IMPOSED UPON SUCH PERSON IN CONNECTION WITH ANY THREATENED, PENDING OR COMPLETED ACTION, SUIT OR PROCEEDING IN WHICH HE OR SHE MAY BECOME INVOLVED BY REASON OF HIS OR HER SERVICE IN SUCH CAPACITY. HOWEVER, NO INDEMNIFICATION WILL BE PROVIDED FOR ANY SUCH PERSON WITH RESPECT TO ANY MATTER IN WHICH THE INDIVIDUAL SHALL HAVE BEEN FINALLY ADJUDICATED TO HAVE NOT ACTED IN GOOD FAITH WITH THE REASONABLE BELIEF THAT SUCH ACTION WAS IN THE BEST INTERESTS OF THE CORPORATION IN ANY PROCEEDING. FURTHER, A MAJORITY VOTE OF A QUORUM OF DIRECTORS WHO ARE NOT AT THAT TIME PARTIES TO THE PROCEEDING SHALL APPROVE ANY COMPROMISE OR SETTLEMENT PAYMENT THEREOF. THE INDEMNIFICATION HEREUNDER PROVIDED WILL INURE TO THE BENEFIT OF THE HEIRS, EXECUTORS, AND ADMINISTRATORS OR OTHER INDIVIDUALS ENTITLED TO INDEMNIFICATION. UNDER THE AUTHORITY OF THIS ARTICLE, THE RIGHT OF INDEMNIFICATION SHALL BE IN ADDITION TO - NOT EXCLUSIVE OF - ALL OTHER RIGHTS TO WHICH ANY INDIVIDUAL MAY BE ENTITLED. AS BETWEEN THE CORPORATION AND ITS INDEMNIFIED OFFICERS AND DIRECTORS, THIS ARTICLE CONSTITUTES A CONTRACT. AMENDMENTS TO OR REPEALS OF THE PROVISIONS OF THIS ARTICLE THAT ADVERSELY AFFECT THE RIGHTS OF AN INDEMNIFIED OFFICER OR DIRECTOR SHALL NOT APPLY TO ANY SUCH OFFICER OR DIRECTOR WITH RESPECT TO THOSE ACTS OR OMISSIONS THAT OCCURRED AT ANY TIME PRIOR TO SUCH AMENDMENT OR REPEAL.

Notes: The preceding four (4) articles are considered to be permanent and may only be changed by filing appropriate Articles of Amendment.

ARTICLE V

The by-laws of the corporation have been duly adopted and the initial directors, president, treasurer and clerk or other presiding, financial or recording officers, whose names are set out on the following page, have been duly elected.

ARTICLE VI

The effective date of organization of the corporation shall be the date approved and filed by the Secretary of the Commonwealth. If a later effective date is desired, specify such date which shall not be more than *thirty days* after the date of filing.

ARTICLE VII

The information contained in Article VII is not a permanent part of the Articles of Organization.


a. The street address (post office boxes are not acceptable) of the principal office of the corporation in Massachusetts is:

No. and Street: 1400 HANCOCK STREET
THIRD FLOOR

City or Town: QUINCY State: MA Zip: 02169 Country: USA

b. The name, residential street address and post office address of each director and officer of the

corporation is as follows:

Title	Individual Name First, Middle, Last, Suffix	Address (no PO Box) Address, City or Town, State, Zip Code	Expiration of Term
PRESIDENT	EDWARD DOW III		cessors elected alified
TREASURER	RONALD RAPOPORT		cessors elected alified
CLERK	MICHAEL MAXIM		cessors elected alified
DIRECTOR	EDWARD DOW III		cessors elected alified
DIRECTOR	RONALD RAPOPORT		cessors elected alified
DIRECTOR	MICHAEL MAXIM		cessors elected alified

c. The fiscal year (i.e., tax year) of the business entity shall end on the last day of the month of:
December

d. The name and business address of the resident agent, if any, of the business entity is:

Name: BRANDON KURTZMAN, ESQ.

No. and Street: 1400 HANCOCK STREET
THIRD FLOOR

City or Town: QUINCY State: MA Zip: 02169 Country: USA

I/We, the below signed incorporator(s), do hereby certify under the pains and penalties of perjury that I/we have not been convicted of any crimes relating to alcohol or gaming within the past ten years. I/We do hereby further certify that to the best of my/our knowledge the above-named officers have not been similarly convicted. If so convicted, explain:


IN WITNESS WHEREOF AND UNDER THE PAINS AND PENALTIES OF PERJURY, I/we, whose signature(s) appear below as incorporator(s) and whose name(s) and business or residential address (es) beneath each signature do hereby associate with the intention of forming this business entity under the provisions of General Law, Chapter 180 and do hereby sign these Articles of Organization as incorporator(s) this 8 Day of December, 2017. (If an existing corporation is acting as incorporator, type in the exact name of the business entity, the state or other jurisdiction where it was incorporated, the name of the person signing on behalf of said business entity and the title he/she holds or other authority by which such action is taken.)

BRANDON KURTZMAN, ESQ., ATTORNEY FOR SOLAR THERAPEUTICS INC.

THE COMMONWEALTH OF MASSACHUSETTS

I hereby certify that, upon examination of this document, duly submitted to me, it appears that the provisions of the General Laws relative to corporations have been complied with, and I hereby approve said articles; and the filing fee having been paid, said articles are deemed to have been filed with me on:

December 08, 2017 11:35 AM

A handwritten signature in black ink, reading "William Francis Galvin". The signature is written in a cursive style with a large, stylized initial "W".

WILLIAM FRANCIS GALVIN

Secretary of the Commonwealth



William Francis Galvin
Secretary of the
Commonwealth

The Commonwealth of Massachusetts
Secretary of the Commonwealth
State House, Boston, Massachusetts 02133


Date: January 24, 2018

To Whom It May Concern :

I hereby certify that according to the records of this office,
SOLAR THERAPEUTICS INC.

is a domestic corporation organized on **December 08, 2017**

I further certify that there are no proceedings presently pending under the Massachusetts General Laws Chapter 180 section 26 A, for revocation of the charter of said corporation; that the State Secretary has not received notice of dissolution of the corporation pursuant to Massachusetts General Laws, Chapter 180, Section 11, 11A, or 11B; that said corporation has filed all annual reports, and paid all fees with respect to such reports, and so far as appears of record said corporation has legal existence and is in good standing with this office.



In testimony of which,
I have hereunto affixed the
Great Seal of the Commonwealth
on the date first above written.

William Francis Galvin

Secretary of the Commonwealth

Certificate Number: 18010422820

Verify this Certificate at: <http://corp.sec.state.ma.us/CorpWeb/Certificates/Verify.aspx>

Processed by:

BY-LAWS OF SOLAR THERAPEUTICS, INC.
A MASSACHUSETTS NON-PROFIT CORPORATION

ARTICLE I: GENERAL

Section 1. Name and Purposes. The name of the Corporation is Solar Therapeutics, Inc. (the “Corporation”). The purpose of the Corporation shall be as set forth in the Corporation’s Articles of Organization as adopted and filed with the Office of the Secretary of State of the Commonwealth of Massachusetts (as now in effect or as hereafter amended or restated from time to time, the “Articles of Organization”) pursuant to Chapter 180 of the Massachusetts General Laws, as now in effect and as hereafter amended, or the corresponding provision(s) of any future Massachusetts General Law (“Chapter 180”). The Corporation shall, at all times, operate on a non-profit basis for the benefit of registered qualifying patients and shall ensure that revenue of the Non-Profit is used solely in furtherance of its nonprofit purpose.

Section 2. Articles of Organization. These By-Laws (“By-Laws”), the powers of the Corporation and its Member(s) and Board of Directors, and all matters concerning the conduct and regulation of the business of the Corporation, shall be subject to the provisions in regard thereto that may be set forth in the Articles of Organization. In the event of any conflict or inconsistency between the Articles of Organization and these By-Laws, the Articles of Organization shall control.

Section 3. Corporate Seal. The Board of Directors may adopt and alter the seal of the Corporation. The seal of the Corporation, if any, shall, subject to alteration by the Board of Directors, bear its name, the word “Massachusetts” and the year of its incorporation.

Section 4. Fiscal Year. The fiscal year of the Corporation shall commence on January 1, and end on December 31 of each year, unless otherwise determined by the Board of Directors.

Section 5. Location of Offices of Corporation. The principal office of the Corporation shall be 2 Seaport Lane, c/o Vicente Sederberg LLC, Boston, MA 02210. The Board of Directors may approve a change of the location of the principal office in the Commonwealth of Massachusetts effective upon the filing of a certificate indicating the new location with the Office of the Secretary of State of the Commonwealth of Massachusetts. The Corporation may establish and maintain offices in such other locations, within and outside of the Commonwealth of Massachusetts, as the Board of Directors may determine.

ARTICLE II: MEMBERS

Section 1. Identity of Initial and Sole Member. The initial and sole member of the Corporation shall be Edward Dow (hereinafter referred to herein as the “Member”). In the event the Member dies or becomes incapacitated and, at that time, there are no other Additional Members (as defined below), the legal representative of the estate of the Member shall be vested with exclusive authority to appoint a substitute Member, subject to such terms and conditions, including terms and

conditions with respect to voting rights, as such legal representative may determine to be appropriate at the time of such appointment.

Section 2. Additional and Substitute Members. The Member has the power to appoint additional members or substitute members of the Corporation ("**Additional Members**"), and the Member may amend these By-Laws to provide for the admission of Additional Members on such terms and conditions as the Member may determine.

Section 3. Tenure. For so long as the Member continues to comply with the qualifications, rules and regulations applicable to Membership as shall be established from time to time by the Member, the Member shall continue to be a Member in good standing until the Member dies, resigns, withdraws, dissolves, becomes incapacitated or disqualified, unless a different term is designated at the time the By-Laws are amended and an Additional Member is admitted by the Member.

Section 4. Resignation. The Member and any Additional Member may resign by delivering a written resignation to the President or Clerk of the Corporation, to the Board of Directors, or to the principal office of the Corporation. Such resignation shall be effective upon receipt (unless specified to be effective at another time), and acceptance thereof shall not be necessary to make it effective. The Member shall appoint a substitute member in accordance with Section 1 of this Article.

Section 5. Annual Meeting. The annual meeting of the Member shall be held on such day and at such hour as may be determined by the Member. In the event that the annual meeting is not held on such date, a special meeting in lieu thereof may be held with all of the force and effect of an annual meeting.

Section 6. Special Meetings. Special meetings of the Member may be called by the Member, the President or by a majority of the Directors, and shall be noticed by the Clerk, or in the case of the death, absence, incapacity or refusal of the Clerk, by any other officer.

Section 7. Notice. In the event that there are Additional Members, written notice of the date, place, and hour of all meetings stating the purposes of the meeting shall be given by the Member or the Clerk at least two (2) calendar days before the meeting to the Members. The Members may waive notice either before or after a meeting. If there are no Additional Members, notice of an annual or special meeting shall not be required.

Section 8. Action by Written Consent. Any action required or permitted to be taken at any meeting of the Member may be taken without a meeting and without notice if the Member consents to the action in writing and the written consent is filed with the records of the meetings of the Member. Such consent shall be treated for all purposes as a vote at a meeting.

Section 9. Powers of the Member. In addition to and without limiting the powers, rights and privileges the Member shall have that are afforded to "members" of a Corporation organized under Chapter 180, the Articles of Organization, these By-Laws and other applicable law, the actions and powers of the Corporation listed below shall be reserved exclusively to the Member:

- (a) Amend or amend and restate the Articles of Organization;

- (b) Adopt, amend, or repeal these By-Laws;
- (c) Appoint, remove, or suspend any Director of the Corporation;
- (d) Change the number of members of the Board of Directors of the Corporation;
- (e) Approve any sale or other disposition of all, or substantially all, of the assets or operations of the Corporation;
- (f) Approve any merger or consolidation of the Corporation;
- (g) Approve any plan of dissolution of the Corporation, or other action related to dissolution or liquidation of the Corporation;
- (h) Appoint, suspend, or remove an Additional Member of the Corporation; and
- (i) Authorize the Corporation to enter into any agreement to do any of the foregoing.

ARTICLE III: DIRECTORS

Section 1. Enumeration; Qualifications. The Corporation shall have a Board of Directors that shall serve as the governing body of the Corporation and shall have all the powers and duties of a board of directors under Massachusetts law, except for those powers reserved to the Member or delegated to officers pursuant to these By-Laws. The Board of Directors shall consist of such number of Directors as shall be determined initially by the incorporator, and thereafter by the Member (but not less than the minimum number required by law). Directors shall possess such qualifications as may be determined by the Member.

Section 2. Election of Directors; Term of Office. Directors shall be elected by the Member at an annual meeting of the Member or at any special meeting held in lieu thereof by the affirmative vote of the Member or by written consent of the Member. Subject to other provisions of these By-Laws, unless the Member specifies a different term at the time of election or appointment, each Director shall serve until the next annual meeting of the Member, or special meeting held in lieu thereof, and until his or her successor is duly elected and qualified, or until he or she sooner dies, becomes incapacitated, resigns, is removed or becomes disqualified.

Section 3. Vacancies. Any vacancy at any time existing in the Board of Directors (including any newly created seats on the Board) may be filled by the Member at any meeting of the Member or by written consent of the Member. Unless the Member specifies a different term at the time of election or appointment, each successor Director shall hold office for the remainder of his or her predecessor's unexpired term and until his or her successor is duly elected and qualified, or in each case until he or she sooner dies, resigns, is removed or becomes disqualified.

Section 4. Resignation. Any Director may resign by delivering his or her written resignation to the Corporation at its principal office, to any meeting of the Board of Directors, or to the President or Clerk of the Corporation. Such resignation shall be effective upon receipt (unless it is specified to be effective at some other time or upon the happening of some other event) and acceptance

thereof shall not be necessary to make it effective unless it so states; *provided, however*, that the Board of Directors may act to accept such resignation immediately or at any other time sooner than the time specified by such resigning Director in his or her resignation.

Section 5. Removal. A Director may be removed from office, with or without cause, by the affirmative vote of the Member. A Director may be removed for cause only after reasonable notice and opportunity to be heard prior to action thereon.

Section 6. Powers. The Board of Directors shall manage, control and be responsible for oversight of the affairs and property of the Corporation, and at all times may exercise on behalf of the Corporation all lawful powers, rights and privileges of the Corporation under Chapter 180 and any other applicable law, except those powers reserved to the Member by law, the Articles of Organization, or these By-Laws. The Board of Directors, in its discretion, may from time to time establish committees, appoint individuals to serve as members of any such committee, define or limit the powers and duties of any such committee, and thereafter may disband the same. The Board of Directors may delegate its powers, or a portion thereof, to committees that either consist solely of Directors or give voting power only to Directors on any such committee, except that the Board of Directors may not delegate the powers specified in Section 55 of Chapter 156B of the Massachusetts General Laws or other actions under Massachusetts law that require action by the Board of Directors including, without limitation, the Board may not delegate to a committee the power to:

- (a) Change the location of the principal office of the Corporation;
- (b) Adopt, amend or repeal these By-Laws;
- (c) Change the number of Directors;
- (d) Appoint, elect, suspend or remove Directors or officers;
- (e) Amend or amend and restate the Articles of Organization;
- (f) Authorize any sale, lease, exchange or other disposition of all or substantially all of the assets of the Corporation;
- (g) Authorize any merger or consolidation of the Corporation; or
- (h) Authorize the dissolution of the Corporation.

Subject to these By-Laws and applicable law, the Board of Directors may authorize officers, attorneys or agents of the Corporation to act on its behalf subject to such limitations as the Board of Directors determines.

Section 7. Compensation of Directors. Directors as such shall not receive any salaries for their services on the Board of Directors of the Corporation, but Directors shall not be precluded from serving the Corporation in any other capacity and receiving reasonable compensation for any such services. The Corporation may reimburse Directors for reasonable expenses incurred in the performance of their duties to the Corporation as approved by the Board of Directors. A Director, solely because of being a member of the Board of Directors, shall not be precluded from serving

the Corporation in any other capacity and receiving reasonable compensation for any such other service.

ARTICLE IV: MEETINGS OF THE BOARD OF DIRECTORS

Section 1. Place. Meetings of the Board of Directors shall be held at such place within or outside of Massachusetts as may be determined by the Board and identified in the notice of any such meeting.

Section 2. Annual and Special Meetings. Annual meetings of the Board of Directors may be held at such time as may be determined by the majority of the Directors and identified in the notice of such meeting. Special meetings of the Board may be called by the Member, the President or by a majority of the Directors, and shall be noticed by the President or the Clerk, or in the case of the death, absence, incapacity or refusal of the President or the Clerk, by the Member or any other officer.

Section 3. Notice. Unless otherwise required by law, the Articles of Organization, or these By-Laws, notice of each meeting of the Board of Directors shall be given, not later than two (2) business days before the meeting is scheduled to commence, by the President or the Clerk (or the Member or other officer as set forth in Section 1 above) and each such notice shall state the place, date and time of the meeting. Notice of each meeting may be delivered to a Director by hand or given to a Director orally (either by telephone or in person) or mailed, sent by electronic mail or sent by facsimile transmission to a Director at his residence or usual place of business. If mailed, the notice shall be deemed given when deposited in the United States mail, postage prepaid; if sent by electronic mail, the notice shall be deemed given when directed to an electronic mail address at which the Director has consented to receive notice; and if sent by facsimile transmission, the notice shall be deemed given when transmitted with transmission confirmed. Notice of any meeting need not be given to any Director who shall submit, either before or after the time stated therein, a signed waiver of notice or who shall attend the meeting, other than for the express purpose of objecting at the beginning thereof to the transaction of any business because the meeting is not lawfully called or convened. Notice of an adjourned meeting, including the place, date and time of the new meeting, shall be given to all Directors not present at the time of the adjournment, and also to the other Directors unless the place, date and time of the new meeting are announced at the meeting at the time at which the adjournment is taken.

Section 4. Quorum; Action at Meetings; Proxy Voting Not Permitted. Except as otherwise provided by law, the Articles of Organization or these By-Laws, at all meetings of the Board of Directors, a majority of the total number of Directors then in office shall constitute a quorum for the transaction of business, and the vote of a majority of the Directors present and voting at a meeting when a quorum is present shall be the act of the Board. A majority of the Directors present, whether or not a quorum is present, may adjourn any meeting to another time, date and place. Each Director shall be entitled to one (1) vote on any matter that comes before the Board of Directors. There shall be no voting by proxy.

Section 5. Action by Written Consent. Any action required or permitted to be taken at any meeting of the Directors may be taken without a meeting and without notice if a majority of all of the Directors consent to the action in writing and the written consents are filed with the records of the meetings of the Directors. Such consents shall be treated for all purposes as a vote at a meeting.

Section 6. Presence through Communications Equipment. Unless otherwise restricted by law, members of the Board of Directors or any committee thereof may participate in a meeting by means of a conference telephone or similar communications equipment so that all persons participating in the meeting can hear each other at the same time and participation by such means shall constitute presence in person at the meeting.

ARTICLE V: OFFICERS AND AGENTS

Section 1. Enumeration. The officers of the Corporation shall be: President, Treasurer, Clerk, and such other officers, if any, as the Board of Directors may from time to time determine. The Corporation may also have such agents as the Board of Directors may appoint from time to time and each shall have such powers as may be designated by the Board of Directors.

Section 2. Term of Office. Unless the Board of Directors indicate a different term at the time of election or appointment, officers of the Corporation shall serve at the pleasure of the Board of Directors, and until their respective successors are elected and qualified, or in each case until he or she sooner dies, resigns, is removed or becomes disqualified.

Section 3. Qualifications. An officer of the Corporation may but need not be a Director of the Corporation. Any two (2) or more offices may be held by the same person. The Clerk shall be a resident of the Commonwealth of Massachusetts unless the Corporation has a resident agent appointed for the purpose of service of process. Any officer may be required by the Directors to give bond for the faithful performance of his or her duties to the Corporation in such amount and with such sureties as the Directors may determine. The premiums for such bonds may be paid by the Corporation. Officers shall meet such other qualifications as the Board of Directors may determine from time to time.

Section 4. Vacancies. Any vacancy at any time existing in any officer position of the Corporation may be filled by the Directors and such successor officer shall serve at the pleasure of the Board of Directors, and until his or her successor is chosen and qualified, or in each case until he or she sooner dies, resigns, is removed or becomes disqualified.

Section 5. Resignation. Any officer or agent may resign by delivering his or her written resignation to the Corporation at its principal office, to any meeting of the Board of Directors, or to the President or Clerk of the Corporation, and such resignation shall be effective upon receipt (unless it is specified to be effective at some other time or upon the happening of some other event) and the acceptance thereof shall not be necessary to make it effective unless it so states; *provided, however*, that the Board of Directors may act to accept such resignation immediately or at any other time sooner than the time specified by such resigning officer in his or her resignation.

Section 6. Removal. The Board of Directors may remove any officer, with or without cause, by the affirmative vote of a majority of the total number of Directors then in office at any regular

meeting or special meeting of the Board of Directors. An officer may be removed for cause only after reasonable notice and opportunity to be heard prior to action thereon. Each agent appointed by the Board shall retain his or her authority at the pleasure of the Board of Directors and each agent so appointed may be removed, with or without cause, at any time by the Board of Directors.

Section 7. President. The President shall be the chief executive officer of the Corporation and as such shall have charge of the general business and affairs of the Corporation subject to the supervision of the Board of Directors. Subject to limitations that the Board of Directors may approve generally or in any specific instance, the President shall have the power to bind the Corporation and execute documents on behalf of the Corporation, including signing checks or drawdowns on bank accounts of the Corporation. The President shall also have such other powers and duties as customarily belong to the office of the chief executive and any other powers as may be designated from time to time by the Board of Directors. The President shall be responsible for the administration of the Corporation in all its activities subject to such policies as may be adopted and such orders as may be issued by the Board of Directors from time to time, or by any committees of the Board to which the authority for such action has been specifically delegated.

Section 8. Treasurer. The Treasurer shall have such powers and duties as customarily belong to the office of Treasurer and any other powers as may be designated from time to time by the Board of Directors. The Treasurer shall have the power to endorse for deposit or collection all notes, checks, drafts and similar documents that are payable to the Corporation or its order, provided that the Treasurer shall not deposit any funds of the Corporation in any banking institution unless such institution has been designated as a depository by a vote of the majority of the members of the Board of Directors, exclusive of any Director who is an officer or Director of the depository so designated. Subject to limitations that the Board of Directors may approve generally or in any specific instance, all checks drawn on bank accounts of the Corporation may be signed on its behalf by the Treasurer or such other persons as may be authorized from time to time by the Board of Directors.

Section 9. Clerk. The Clerk shall record all proceedings of the Member and the Board of Directors in a book or books to be kept therefor and shall have custody of the seal of the Corporation. If the Clerk is absent from any meeting of the Board of Directors, a temporary Clerk shall be chosen at the meeting who shall keep a true record of the proceedings thereof.

Section 10. Additional Powers and Duties. Each officer shall, subject to these By-Laws and to any applicable provisions of law and the Articles of Organization, have, in addition to the duties specifically set forth in these By-Laws, such duties and powers as are customarily incident to such officer's office and such additional duties and powers as the President or the Directors may from time to time designate.

Section 11. Compensation of Agents and Employees. The Corporation may pay compensation in reasonable amounts to its officers, agents and employees for services rendered, such amount to be fixed by the Board of Directors, or, if the Board of Directors delegate power to any officer or officers, then by such officer or officers; *provided, however*, any such officer or officers authorized by the Board of Directors to fix compensation may not be authorized to fix his or her own

compensation. The Directors may require officers, agents or employees to give security for the faithful performance of their duties.

ARTICLE VI: MAINTENANCE AND INSPECTION OF RECORDS

The original, or attested copies, of the Articles of Organization, these By-Laws and records of all meetings and actions of the Member, the Board of Directors and its committees, and records which shall contain the names of all Directors and their record addresses, shall be kept in the Commonwealth of Massachusetts at the principal office of the Corporation, or at an office of the Clerk, attorney of record or the resident agent, if any, of the Corporation. Books, accounts, documents and records of the Corporation shall be open to inspection by any Director or Member for any proper purpose during the usual hours of business.

ARTICLE VII: EXECUTION OF INSTRUMENTS; EVIDENCE OF AUTHORITY

Section 1. Checks, Notes, Drafts and Other Instruments. The President and the Treasurer, or other officers and/or agents as shall be authorized by the Board of Directors, are authorized to sign, seal, acknowledge, and deliver, in the name and on behalf of the Corporation: (i) all checks, notes, drafts, and other instruments for the payment of money drawn or endorsed in the name of the Corporation; and (ii) contracts, leases, transfers, conveyances, deeds, notes, bonds and all other written instruments. Any instrument purporting to affect an interest in real estate, executed in the name of the Corporation, shall be executed by any two (2) officers of the Corporation, at least one of whom shall be the President or the Treasurer of the Corporation and shall be binding on the Corporation in favor of a purchaser or other person relying in good faith on such instrument.

Section 2. Evidence of Authority. A certificate executed by the Clerk, an assistant clerk or a temporary clerk as to any action taken by the Member, the Board of Directors, or any officer or representative of the Corporation shall, as to all persons who rely thereon in good faith, be conclusive evidence of such action.

ARTICLE VIII: CONFLICT OF INTEREST

Section 1. Conflict of Interest Policy. All Directors, officers and other persons in a position of significant authority designated by the Board of Directors or the President of the Corporation shall adhere to the Conflicts of Interest Policy attached hereto, which may be amended or replaced from time to time by the Board of Directors.

ARTICLE IX: PERSONAL LIABILITY; INDEMNIFICATION

Section 1. Personal Liability. The Member, Directors and officers of the Corporation shall not be personally liable for any debt, liability or obligation of the Corporation. All persons, corporations or other entities extending credit to, contracting with, or having any claim against, the Corporation, may look only to the funds and property of the Corporation for the payment of any such contract or claim, or for the payment of any debt, damages, judgment or decree, or of any money that may otherwise become due or payable to them from the Corporation.

Section 2. Indemnification. The Corporation shall, to the fullest extent legally permissible, indemnify each Indemnified Person (as defined below) against all liabilities and losses, including amounts paid in satisfaction of judgments, in compromise or as fines, penalties, excise taxes, court costs, witness fees, and Costs and Expenses (as defined below) incurred by, or imposed upon, the Indemnified Person in connection with or arising out of the defense or disposition of any Proceeding (as defined below) in which the Indemnified Person is or may become involved or with which the Indemnified Person may be threatened, while in office or thereafter, as a party, witness or otherwise, by reason of his or her being or having been an Indemnified Person.

Notwithstanding the foregoing, as to any matter disposed of by a compromise payment by an Indemnified Person, pursuant to a consent decree or otherwise, no indemnification for said payment shall be provided unless such compromise and indemnification therefor shall be approved:

- (a) By a majority vote of disinterested Directors;
- (b) If there are not two or more disinterested Directors in office, then by a majority of the Directors then in office, provided they have obtained a written finding by Independent Legal Counsel (as defined below) appointed by a majority of the Directors to the effect that, based upon a reasonable investigation of the relevant facts as described in such opinion, the Indemnified Person appears to have acted in good faith and in the reasonable belief that the Indemnified Person's actions were in the best interests of the Corporation (or, to the extent that such matter relates to service with respect to a Related Entity, in the best interests of the Related Entity (and, if the Related Entity is an employee benefit plan, in the best interests of the participants or beneficiaries of such plan)); and with such care as an ordinarily prudent person in a like position with respect to a similar corporation organized under Chapter 180 would use under similar circumstances;
- (c) By the Member if she is disinterested; or
- (d) By a court of competent jurisdiction.

Costs and Expenses incurred by an Indemnified Person in connection with the defense or disposition of any Proceeding shall be paid promptly by the Corporation in advance of the final disposition thereof upon receipt of an undertaking by such Indemnified Person to repay the amounts so paid by the Corporation if it is ultimately determined that indemnification for such Costs and Expenses is not authorized by law or under this Article. Such undertaking shall be accepted without reference to the financial ability of such Indemnified Person to make repayment.

If both the Corporation and the Indemnified Person are parties to a Proceeding (other than a claim, action or suit by or in the right of the Corporation to procure a judgment in its favor), counsel representing the Corporation therein also may represent such Indemnified Person (unless such dual representation would involve such counsel in an actual or potential conflict of interest in violation

of applicable principles of professional ethics), and the Corporation shall pay all Costs and Expenses of such counsel incurred during the period of dual representation.

The right of indemnification hereby provided shall not be exclusive. Nothing contained in this Article shall affect any rights to indemnification to which such Indemnified Person or other corporate personnel may be entitled by contract, by vote of the Board of Directors or otherwise under law.

Section 3. Definitions. As used in this Article IX, the terms:

- (a) **“Costs and Expenses”** means all reasonable costs and expenses incurred by an Indemnified Person in investigating, defending or appealing any Proceeding, including attorneys’, accountants’, experts’ and other professional fees and disbursements; reasonable compensation for time spent by the Indemnified Person on behalf of the Corporation during which he or she is not otherwise compensated by the Corporation or a third party; any premium, security for, and other costs relating to any costs or other appeal bond or its equivalent, whether such Proceeding is of a civil, criminal, arbitrational, administrative or investigative nature, whether formal or informal, including an action by or in the name of the Corporation. Costs and Expenses shall include all reasonable costs and expenses incurred by an Indemnified Person, including attorneys’, accountants’, experts’ and other professional fees and disbursements, in connection with successfully establishing his or her right to indemnification, in whole or in part, hereunder.
- (b) **“Indemnified Person”** means each person who:
 - (i) Shall be, or at any time shall have been a Member, a Director or an officer of the Corporation; or
 - (ii) At the request of the Corporation, shall serve, or at any time shall have served, as an incorporator, director, trustee, officer, employee, agent, member, manager or in any other capacity with respect to any Related Entity; or
 - (iii) The Board of Directors by vote shall designate, who shall be, or at any time shall have been, an employee or agent of the Corporation or who shall serve, or at any time shall have served, at the request of the Corporation, in any capacity with respect to any Related Entity.
- (c) **“Proceeding”** means any threatened, pending or completed claim, action, suit or proceeding or any alternative dispute resolution mechanism (including an action by or in the right of the Corporation or an affiliate of the Corporation) or any formal or informal inquiry, hearing or investigation, whether conducted by the Corporation or an affiliate of the Corporation or any other party, and any other action that an Indemnified Person in good faith believes might lead to the institution of any such action, suit or

proceeding, whether civil, criminal, arbitrational, administrative, investigative or other, including any appeal relating to any of the foregoing.

- (d) **"Related Entity"** means any corporation, limited liability company, partnership, joint venture, trust or other entity or enterprise in which the Corporation is in any way interested in, or as to which an Indemnified Person is serving or shall have served at the Corporation's request or on its behalf, as a director, officer, partner, employee, agent, fiduciary, member, manager or representative including, but not limited to, any employee benefit plan or any corporation of which the Corporation or any Related Entity is, directly or indirectly, a stockholder, member, limited or general partner, beneficiary or creditor.
- (e) **"Independent Legal Counsel"** means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the previous five (5) years has been retained to represent: (A) the Corporation or the Indemnified Person in any other matter material to either party, or (B) any other party to the threatened, pending or completed proceeding or action giving rise to the claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Legal Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Corporation or the Indemnified Person in a proceeding or action to determine the Corporation's obligations or such Indemnified Person's rights hereunder.
- (f) "Person," "director," "officer," "employee," "agent" and "Indemnified Person" shall include their respective heirs, executors and administrators, and an "interested" director, officer, employee or agent is one against whom in such capacity the Proceedings in question or other Proceedings on the same or similar grounds is then pending.

Section 4. Enforceability. It is the intention of the Corporation that the obligations of the Corporation, and the rights and benefits of Indemnified Persons shall vest upon the date of adoption of these By-Laws. It is the further intention of the Corporation to provide for indemnification in all cases under all circumstances where to do so would not violate applicable law (and notwithstanding any limitations permitted, but not required by statute or common law) and the terms and provisions of this Article shall be interpreted and construed consistent with that intention. Nonetheless, if any term or provision of this Article, or the application thereof to any person or circumstances, shall to any extent be held invalid or unenforceable, the remainder of this Article IX, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Article IX shall be held valid and be enforced to the fullest extent permitted by law. Any amendment, alteration or repeal of this Article IX or Chapter 180 that adversely affects any right of an Indemnified Person (or his or her respective heirs, executors and administrators), shall be prospective only and shall not limit or eliminate any such right with

respect to any Proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to any such amendment, alteration or repeal.

Section 5. Insurance. The Corporation shall have the power to purchase and maintain insurance on behalf of any Indemnified Person against any liability asserted against or incurred by him or her in such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify or advance expenses to him or her against such liability.

ARTICLE X: ADVISORY BOARDS OR COMMITTEES

The Board of Directors may determine to establish one or more advisory boards or committees to further the goals of the Corporation. Advisory boards or committees may be constituted of persons who are not Directors, but have an interest and willingness to advance the purposes of the Corporation. Any advisory board or committee may be discontinued by the Board of Directors at any time. An advisory board or committee shall be required to make at least annual reports to the Board of Directors.

ARTICLE XI: NONDISCRIMINATION POLICY

Persons of all races, religions, genders, sexual orientations and national origins shall be entitled to all the rights and privileges generally made available by the Corporation through the activities and programs that it conducts, and the Corporation shall not discriminate on the basis of race, religion, gender, sexual orientation, national origin or disability.

ARTICLE XII: AMENDMENTS

These By-Laws may be altered, amended or repealed, in whole or in part, solely by the Member.

ARTICLE XIII: NON-PROFIT COMPLIANCE


In compliance with 105 CMR 725.100(A)(1) and the DPH "*Guidance for Registered Marijuana Dispensaries Regarding Non-Profit Compliance*," the Corporation shall at all times operate on a non-profit basis for the benefit of registered qualifying patients and shall ensure that revenue of the Corporation is used solely in furtherance of its non-profit purpose.

ARTICLE XIV: POLICIES

The Board of Directors may adopt policies that shall be incorporated into these By-Laws. The following policies have been adopted and incorporated herein:

- Appendix 1: Conflict of Interest Policies and Procedures
- Appendix 2: Whistleblower Policy
- Appendix 3: Document Retention and Destruction Policy
- Appendix 4: Compensation Setting Policy
- Appendix 5: Comprehensive Information Security Policy
- Appendix 6: Antitrust Policy

I, Edward Dow, the President of Solar Therapeutics Inc., do hereby attest that the foregoing is a true copy of the By-Laws of the Corporation and that said By-Laws were duly adopted on January 23, 2018.

By: 

Name: Edward Dow

Title: President of Solar Therapeutics Inc.

Appendix 1

SOLAR THERAPEUTICS INC. CONFLICT OF INTEREST POLICIES AND PROCEDURES

I. PURPOSE

SOLAR THERAPEUTICS INC. (the "Corporation") must be aware of and diligently address and manage all conflicts of interest and appearances of any conflicts of interest in order to protect the best interest of the Corporation when it is contemplating entering a transaction that might benefit the private interest of directors, members, officers or the executive management team. The Board of Directors shall follow the procedures set forth herein to address and evaluate conflicts of interest to determine whether it is in the best interest of the Corporation to enter into the proposed transaction and, if so, to ensure that the terms of the transaction are fair and reasonable.

II. DEFINITIONS

An *Insider* is a member, director or officer of the Corporation or a person on the executive management team.

An *Interest* means any material financial interest, direct or indirect, including, but not limited to, a sale, loan or exchange with the Corporation whereby the Insider would derive a material financial benefit, but shall not include compensation in the form of salary, such compensation being governed by the Compensation Setting Policy.

A *Managerial Position* is a member, director, officer, executive, trustee, or other managerial role in an entity other than the Corporation or a person who has significant influence over the management or operating policies of an entity other than the Corporation.

Transaction means any transaction, agreement, or arrangement with the Corporation.

A *Conflict of Interest* is present when an Insider, or an immediate family member of an Insider, has an Interest in a Transaction or is in a Managerial Position with an entity involved in a Transaction.

Disinterested Directors are the members of the Board of Directors of the Corporation that do not have a Conflict of Interest.

III. PROCEDURES

1. Duty to Disclose

Promptly upon learning of the proposed Transaction, each Insider that has a Conflict of Interest shall promptly disclose to the Board of Directors the existence of the Conflict of Interest and all material facts regarding their Interest in the Transaction, including relevant

Managerial Positions. Such disclosure shall be made prior to the Board of Directors taking any action on the Transaction or substantially discussing the Transaction. In the event that the Insider is unsure as to whether a Conflict of Interest exists, the Insider shall disclose the circumstances to the Disinterested Directors, who shall determine whether there exists a Conflict of Interest that is subject to this policy.

2. No Participation

An Insider who has a Conflict of Interest shall not take part in any negotiations regarding the Transaction and shall not participate in or be permitted to attend the Board's or any committee's discussion of the matter except to disclose material facts and to respond to any questions regarding the Insider's Conflict of Interest. The Insider with the Conflict of Interest shall not exert his or her personal influence or lobby the Board of Directors with respect to the matter, either at or outside the meeting, and shall not vote on the Transaction. An Insider who is a member of the Board of Directors may be counted in determining the presence of a quorum at such meeting, however, the interested Directors may not be present during any discussion or vote on the Transaction.

3. Due Diligence

The Disinterested Directors shall hold a meeting to determine if the Transaction is fair, reasonable and in the best interest of the Corporation by conducting due diligence on the Transaction. Such due diligence may include any or all of the following:

- Reviewing all relevant documents relating to the Transaction;
- Discussing the purpose, benefits, advantages and disadvantages of the Transaction;
- Reviewing similar agreements and transactions to compare the relevant terms to the Transaction;
- Discussing and considering alternatives to the Transaction;
- Obtaining opinions or guidance from relevant industry third-party professionals regarding the fairness of the Transaction and the industry standards and terms for similar transactions;
- Consulting with the Corporation's legal counsel to discuss the terms and legal implications of the Transaction;
- Obtaining an independent legal opinion that the Transaction is fair, in the best interest of the Corporation and in compliance with applicable laws and regulations; and
- Proposing modification to the terms of the Transaction if the Disinterested

Directors concluded that the proposed terms of the Transaction are not fair, reasonable and in the best interest of the Corporation, as presented.

4. Approval

After exercising its due diligence, the Disinterested Directors, shall determine whether the Transaction is fair, reasonable and in the best interest of the Corporation. The Transaction can be approved by a majority vote of the Disinterested Directors present at a meeting for which a quorum is present. The Transaction must be approved by more than one Disinterested Director.

5. Record of Proceedings

The minutes of any meeting of the Board of Directors held pursuant to this policy shall contain:

- the names of all persons present at the meeting;
- details of the Transaction;
- the name of each Insider who disclosed or was otherwise determined to have a Conflict of Interest;
- the nature of the Conflict of Interest;
- the names of the Directors who participated in the discussion regarding the Transaction and the names of the Directors who were excluded from discussions of the Transaction;
- the information considered and discussed by the Board in exercising its due diligence regarding the Transaction;
- the Directors who voted on the Transaction, and the Directors who were excluded from voting;
- the result of the vote;
- if the Board rejected the Transaction, the reasons for the rejection and any proposed modifications to the Transaction;
- if the Board approved the Transaction, the reasons why the Board determined that the Transaction is fair and in the best interest of the Corporation; and
- copies of the Transaction agreements and all related documents thereto.

IV. VIOLATIONS

If the Board of Directors has reasonable cause to believe that an Insider has failed to disclose a Conflict of Interest, it shall inform such Insider of the basis for this belief and afford the Insider an opportunity to explain the alleged failure to disclose. If, after hearing the Insider's

response and making further investigation as warranted by the circumstances, the Board of Directors determines that the Insider has failed to disclose a Conflict of Interest, the Board of Directors shall take appropriate disciplinary and corrective action.

V. REVIEW

To ensure that the Corporation operates in a manner consistent with its mission, the Board of Directors shall periodically review this policy. The review shall consider the level of compliance with the policy, the continuing suitability of the policy, and whether the policy should be modified and improved. A copy of this policy shall be distributed to each Insider for their review and compliance hereto.

* * * *

Appendix 2

SOLAR THERAPEUTICS INC. WHISTLEBLOWER POLICY

I. EXPECTATION

SOLAR THERAPEUTICS INC. (the "Corporation") expects Directors, Officers and employees to observe high ethical standards in carrying out their responsibilities and to comply with all applicable laws and regulations.

II. OPEN DOOR POLICY

If any Director, Officer or employee has complaints, concerns, or questions as to the ethics or legality of a particular action taken by another Director, Officer or employee, he/she is encouraged to raise such complaints, concerns or questions with the relevant individual. With respect to Directors, the relevant individual is the President of the Board of Directors or any other Director. With respect to Officers and employees, the relevant individual is the President, if there is one in office, and if not, any Director. In the event the Director, Officer or employee believes there may have been a legal transgression, and that it is not reasonable to raise the issue with a Director or the President, he/she should contact an outside attorney. Anyone filing a complaint concerning a violation or suspected violation of a law, regulation or ethical requirement must be acting in good faith and have reasonable grounds for believing the information disclosed indicates a violation. Individuals making baseless or malicious accusations will be disciplined up to and including termination.

III. REQUIREMENT OF INVESTIGATION

Within a reasonable time of receiving a complaint, concern or question regarding compliance with a law, regulation or ethics requirement, the President and/or a Director shall open an investigation into the matter and pursue it to resolution. Should the President or a Director find that a law, regulation or ethics requirement has been violated, appropriate action should be taken.

IV. CONFIDENTIALITY

To the degree possible, the names of the individuals reporting under this Whistleblower Policy shall be kept confidential.

V. PROTECTION FROM RETALIATORY ACTION

Neither the Corporation nor its managers may take any negative employment or other retaliatory action against any Director, Officer or employee who in good faith reports a violation of a law or regulatory requirement. An employee who retaliates against someone

who has reported a violation in good faith is subject to discipline including, but not limited to, termination of employment.

VI. GENERAL POLICY

This general policy is not a contract and it may be rescinded or amended at any time by the Corporation. It is not intended to and does not create any legally enforceable rights whatsoever for any employee.

* * * *

Appendix 3

SOLAR THERAPEUTICS INC. DOCUMENT RETENTION AND DESTRUCTION POLICY

I. RETENTION POLICY

SOLAR THERAPEUTICS INC. (the "Corporation") takes seriously its obligations to preserve information relating to litigation, audits, and investigations. The information listed in the retention schedule below is intended as a guideline and may not contain all the records the Corporation may be required to keep in the future. From time to time, the Corporation may suspend the destruction of records due to pending, threatened, or otherwise reasonably foreseeable litigation, audits, government investigations, or similar proceedings.

File Category	Item	Retention Period
Corporate Records	<i>By-Laws and Articles of Organization</i>	Permanent
	<i>Corporate resolutions</i>	Permanent
	<i>Board and committee meeting agendas and minutes</i>	Permanent
	<i>Conflict-of-interest disclosure forms</i>	4 years
Finance and Administration	<i>Financial statements (audited)</i>	7 years
	<i>Auditor management letters</i>	7 years
	<i>Payroll records</i>	7 years
	<i>Check register and checks</i>	7 years
	<i>Bank deposits and statements</i>	7 years
	<i>Chart of accounts</i>	7 years
	<i>General ledgers and journals (includes bank reconciliations)</i>	7 years
	<i>Investment performance reports</i>	7 years
	<i>Equipment files and maintenance records</i>	7 years after disposition
	<i>Contracts and agreements</i>	7 years after all obligations end
	<i>Correspondence — general</i>	3 years

Insurance Records	<i>Policies — occurrence type</i>	Permanent
	<i>Policies — claims-made type</i>	Permanent
	<i>Accident reports</i>	7 years
	<i>Safety (OSHA) reports</i>	7 years
	<i>Claims (after settlement)</i>	7 years
	<i>Group disability records</i>	7 years after end of benefits
Real Estate	<i>Deeds</i>	Permanent
	<i>Leases (expired)</i>	7 years after all obligations end
	<i>Mortgages, security agreements</i>	7 years after all obligations end
Tax	<i>IRS Tax returns and related correspondence</i>	Permanent
	<i>IRS Form 1120s</i>	7 years
	<i>State Tax returns</i>	7 years
Human Resources	<i>Employee personnel files</i>	Permanent
	<i>Retirement plan benefits (plan descriptions, plan documents)</i>	Permanent
	<i>Employee handbooks</i>	Permanent
	<i>Workers comp claims (after settlement)</i>	7 years
	<i>Employee orientation and training materials</i>	7 years after use ends
	<i>Employment applications</i>	3 years
	<i>IRS Form I-9 (store separate from personnel file)</i>	Greater of 1 year after end of service, or three years
	<i>Withholding tax statements</i>	7 years
	<i>Timecards</i>	3 years
Technology	<i>Software licenses and support agreements</i>	7 years after all obligations end

II. ELECTRONIC DOCUMENTS AND RECORDS

Electronic documents will be retained as if they were paper documents. Therefore, any electronic files that fall into one of the document types on the above schedule will be maintained for the appropriate amount of time. If a user has sufficient reason to keep an e-mail message, the message should be printed in hard copy and kept in the appropriate file or moved to an "archive" computer file folder. Backup and recovery methods should be tested on a regular basis.

III. EMERGENCY PLANNING

The Corporation's records should be stored in a safe, secure, and accessible manner. Documents and financial files that are essential to keeping the Corporation operating in an emergency should, if possible, be duplicated or backed up at least weekly and maintained off-site.

IV. DOCUMENT DESTRUCTION

Documents should be eliminated at the end of the relevant retention period. Destruction of financial and personnel-related documents should be accomplished by shredding. Document destruction with respect to relevant documents will be suspended immediately, upon any indication of an official investigation or when a lawsuit is filed or appears imminent. Destruction will be reinstated upon conclusion of the investigation or lawsuit.

V. COMPLIANCE

The Corporation will periodically review these procedures with legal counsel or the Corporation's certified public accountant to ensure that they are in compliance with new or revised regulations.

* * * *

**SOLAR THERAPEUTICS INC.
COMPENSATION SETTING POLICY**

I. INTRODUCTION

This policy codifies the procedures by which the Board of Directors of SOLAR THERAPEUTICS INC. (the "Corporation") sets the compensation of Directors, top management officials, Officers and key employees ("executive compensation"). These procedures are designed to comply with the "safe harbor" requirements set forth in the tax regulations on intermediate sanctions to create a rebuttable presumption of reasonableness in compensation levels.

II. POLICY

The Board of Directors shall oversee the setting of executive compensation and shall (1) determine compensation of all Directors, top management officials, Officers and key employees, and (2) review, assess and approve the reasonableness of such compensation on a regular basis. In order to be approved as reasonable, compensation must be an amount that would ordinarily be paid for comparable work by similarly situated organizations under like circumstances. The particular education, experience and skill of the compensated individual may also be taken into account.

III. GUIDELINES

Compensation determinations made by the Directors will be made in accordance with the following guidelines:

- (i) In setting and determining the reasonableness of executive compensation, the Board shall obtain and rely upon compensation information for comparable work by similarly situated organizations under like circumstances, as defined in Section II above.
- (ii) Directors involved in setting and approving executive compensation, as well as any third parties providing professional advice to the Directors in connection with setting and approving executive compensation shall be independent and have no conflicts of interest as to the executive whose compensation is being reviewed. Directors shall have no conflict of interest for these purposes if they (1) will not economically benefit from the compensation arrangement, (2) are not family members of a person who will economically benefit, (3) have no material financial interest affected by the compensation arrangement, and (4) are not family members of a person who has a material financial interest affected by the compensation arrangement.

- (iii) Timely and accurate minutes of all final actions by the Board regarding the setting and approval of executive compensation will be recorded and held with Board records. Such minutes will include (1) the terms of the approved compensation arrangement and the date approved, (2) a list of the Directors present during discussion, showing those who approved the arrangement, those who rejected it and those who recused themselves due to conflicts of interest, (3) the comparability data relied upon and how such data was obtained, and (4) the rationale for determining that the arrangement was reasonable if it exceeded the range of the comparability data.

* * * *

Appendix 5

SOLAR THERAPEUTICS INC. COMPREHENSIVE INFORMATION SECURITY POLICY

I. OBJECTIVE

It is the objective of SOLAR THERAPEUTICS INC. (the "Corporation") in the development and implementation of this comprehensive information security program ("CISP") to create effective administrative, technical and physical safeguards for the protection of personal information, and to comply with obligations under 201 CMR 17.00. This CISP sets forth our procedure for evaluating our electronic and physical methods of accessing, collecting, storing, using, transmitting, and protecting personal information. For purposes of this CISP, "personal information" means an individual's first name and last name or first initial and last name in combination with any one or more of the following data elements that relate to such resident: (1) Social Security number; (2) driver's license number or state-issued identification card number; or (3) financial account number, or credit or debit card number, with or without any required security code, access code, personal identification number or password, that would permit access to an individual's financial account; provided, however, that "personal information" shall not include information that is lawfully obtained from publicly available information, or from federal, state or local government records lawfully made available to the general public. The Corporation generally acquires personal information in connection with hiring employees and payroll, and in connection with sales to the public.

II. PURPOSE

The purpose of the CISP is to:

- Ensure the security and confidentiality of personal information;
- Protect against any anticipated threats or hazards to the security or integrity of such information; and
- Protect against unauthorized access to or use of such information in a manner that creates a substantial risk of identity theft or fraud.

III. DATA SECURITY COORDINATOR

The Corporation appoints the Treasurer to be its Data Security Coordinator. The Data Security Coordinator will be responsible for:

- Initial implementation of the CISP;
- Regular testing of the CISP's safeguards;

- Evaluating the ability of each of Corporation's third party service providers to implement and maintain appropriate security measures for the personal information to which Corporation permits them access, and requiring such third party service providers to implement and maintain appropriate security measures;
- Reviewing the scope of the security measures in the CISP at least annually, or whenever there is a material change in the Corporation's business practices that may implicate the security or integrity of records containing personal information; and
- Conducting an annual training session for all Directors, Officers, employees, volunteers and independent contractors, including temporary and contract employees who have access to personal information on the elements of the CISP.

IV. HANDLING PERSONAL INFORMATION

A. Paper Records

All paper records containing personal information shall be kept in a locked file cabinet with restricted access. Paper records will be destroyed regularly in accordance with the Corporation's document destruction policy using an office-grade shredder. Records containing personal information may not be taken out of the office and may be accessed only by personnel with a business necessity. Checks that need to be transported from the dispensary to the bank may be sent by US mail or hand delivered by the responsible employee, and if hand delivered, will not be left unattended at any point in the transition.

Checks. When the Corporation receives checks from members of the public, it will make only one hard copy and keep it in a locked file cabinet with restricted access. The checks themselves will also be kept under lock and key until they are deposited.

Paper Employment Records. Paper employment records must be kept under lock and key and accessed only by staff members responsible for employment issues and/or by the President.

B. Electronically Held Records

The Corporation requires the following security systems with respect to the maintenance of personal information on its computers:

Authentication Protocols. The Data Security Coordinator shall secure user authentication protocols including:

- Control of user IDs and other identifiers;

- A reasonably secure method of assigning and selecting passwords, or use of unique identifier technologies, such as biometrics or token devices;
- Control of data security passwords to ensure that such passwords are kept in a location and/or format that does not compromise the security of the data they protect;
- Restricting access to active users and active user accounts only; and
- Blocking access to user identification after multiple unsuccessful attempts to gain access.

Access Protocols. The Data Security Coordinator shall implement the following secure access control measures:

- Restrict access to records and files containing personal information to those who need such information to perform their job duties; and
- Assign unique identifications plus passwords, which are not vendor supplied default passwords, to each person with computer access, which are reasonably designed to maintain the integrity of the security of the access controls.

Restriction on E-mailing Personal Information. The Corporation will not, as a general rule, send or accept personal information by e-mail. To the extent exceptions must be made, the security measures described in this CISP shall be taken.

Encryption. Should any records and files containing personal information be transmitted across public networks or wirelessly, such records or files shall be encrypted. Personal information stored on laptops and other portable devices shall also be encrypted.

Monitoring. The Corporation shall take all steps necessary to reasonably monitor its computer network for unauthorized use of or access to personal information.

Firewalls. All files containing personal information on a system that is connected to the Internet shall be protected by a reasonably up-to-date firewall protection and operating system security patches designed to maintain the integrity of the personal information.

Virus protection. All computers containing personal information shall be protected by reasonably up-to-date versions of system security agent software, including malware protection and reasonably up-to-date patches and virus definitions, or a version of such software that can still be supported with up-to-date patches and virus definitions, and is set to receive the most current security updates on a regular basis.

B. Vendors

Pursuant to 105 CMR 725.200, information held by the Corporation about dispensary agents is confidential and shall not be disclosed without the written consent of the individual to whom the information applies, or as required under law or pursuant to an order from a court of competent jurisdiction, provided however, the Department may access this information to carry out official duties. Only upon receipt of written consent of the individual to whom the confidential information applies will the Corporation share personal and financial information with its vendors. The Corporation requires each of their vendors to send written evidence, signed by an authorized person, confirming that they follow a confidentiality plan that fully complies with 105 CMR 725.200 and 201 CMR 17.00.

V. TRAINING

The Data Security Coordinator shall ensure that all employees, whether full-time, part-time, seasonal or temporary, and independent contractors, consultants and volunteers who have access to personal information are trained on the data security requirements provided in this CISP.

VI. PERSONS SEPARATING FROM THE CORPORATION

All employees, whether full-time, part-time, seasonal or temporary, and independent contractors, consultants and volunteers upon termination or resignation shall immediately be denied access to physical and electronic records containing personal information and will be required to return or destroy all records and files containing personal information in any form that may at the time of such termination or resignation be in their possession or control, including all such information stored on laptops, portable devices, or other media, or in files, records, notes, or papers.

VII. SECURITY BREACH AND NOTIFICATION

All employees, whether full-time, part-time, seasonal or temporary, and independent contractors, consultants and volunteers, shall as soon as practicable and without unreasonable delay notify the Data Security Coordinator when such person knows or has reason to know of a security breach or when the person knows or has reason to know that personal information was acquired or used by an unauthorized person or used for an unauthorized purpose.

A "security breach" is any unauthorized acquisition or unauthorized use of unencrypted data or, encrypted electronic data and the confidential process or key that is capable of compromising the security, confidentiality, or integrity of personal information that creates a substantial risk of identity theft or fraud. A good faith but unauthorized acquisition of personal information by a person or agency, or employee or agent thereof, for lawful purposes, is not a breach of security unless the personal information is used in an unauthorized manner or subject to further unauthorized disclosure.

When the Data Security Coordinator is informed of a security breach, he or she will (1) notify the individual whose information was compromised, and (2) notify the Massachusetts Attorney General and the Office of Consumer Affairs and Business Regulation.

The notice to the individual will be in writing, possibly by electronic mail, and will include the following information:

- A general description of the incident;
- Identification of the personal information that may be at risk;
- A description of the Corporation's security program;
- A phone number to call within the Corporation for further information;
- Suggestion of extra caution, to review account statements, and to obtain a credit report; and
- Phone numbers and addresses of the Federal Trade Commission, state agencies that may be of assistance, and major consumer reporting agencies. The notice will not be provided if law enforcement personnel advise against it.

The notice to the Office of Consumer Affairs and Business Regulation and to the Attorney General will include the following:

- A detailed description of the nature and circumstances of the breach of security;
- The number of people affected as of the time of notification;
- The steps already taken relative to the incident
- Any steps intended to be taken relative to the incident subsequent to notification; and
- Information regarding whether law enforcement is engaged investigating the incident.

Non-Retaliation. The Corporation will not retaliate against anyone who reports a security breach or non-compliance with CISP, or who cooperates in an investigation regarding such breach or non-compliance. Any such retaliation will result in disciplinary action by the responsible parties up to and including suspension or termination.

Documentation. The Corporation shall document all responsive actions taken in connection with any incident involving a security breach.

VIII. CONFIDENTIALITY

Notwithstanding anything to the contrary contained herein, information held by the Corporation about registered qualifying patients, personal caregivers, and dispensary agents is confidential and shall not be disclosed without the written consent of the individual to whom the information applies, or as required under law or pursuant to an order from a court of competent jurisdiction, provided however, the Department may access this information to carry out official duties.

* * * *

Appendix 6

**SOLAR THERAPEUTICS INC.
ANTITRUST POLICY**

It is the policy of SOLAR THERAPEUTICS INC. (the "Corporation") to comply fully with all federal and state antitrust laws, which prohibit companies from working together to restrict competition. It is also the policy of the Corporation that it and its Member, directors and officers are informed about antitrust laws and recognize possible antitrust issues or questions.

It is legal for competitors within the medical use of marijuana industry to work together, unless such work unlawfully restricts competition within the industry. Although the Corporation's activities generally do not present antitrust issues, to ensure against inadvertent violations of federal and state antitrust laws, except to insure that prices are reasonable and affordable for the Corporation's patients, and to prevent diversion for non-medical purposes, directors, members, officers and employees shall not discuss with competitors the following: increasing, decreasing, or stabilizing prices for medical marijuana or related products and services; and establishing market monopolies for products or services.

Furthermore, directors, officers, members and employees shall not engage in any actions in the context of the Corporation's activities which appear to be anti-competitive in purpose or inconsistent with this policy.

Any questions regarding antitrust issues and the Corporation's activities shall be directed to the President and referred to counsel if deemed necessary.

Pursuant to 105 CMR 725.100(A)(2), no executive, member, director or any entity owned or controlled by such executive, member or director may directly or indirectly control more than three (3) registered marijuana dispensaries in the Commonwealth of Massachusetts.

* * * *

SECTION D. EMPLOYMENT AND EDUCATION FORM

This Employment and Education form must be completed and signed by each of the following individuals: The applicant's Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, individual responsible for marijuana for medical use cultivation operations, and individual responsible for the RMD security plan and security operations. If the applicant does not have a Chief Executive Officer, Chief Operating Officer, or Chief Financial Officer, it must identify the individuals performing the equivalent duties for the Applicant and submit this form for each said individual. Submit one Employment and Education form for each of the above individuals when submitting a *Management and Operations Profile* to the Department of Public Health.

Name of Individual

Edward Dow III

Residential Address of Individual

Title of Individual (at Applicant Corporation)

CEO, COO, CFO

Name of Applicant Corporation

Solar Therapeutics

Highest Education Attained – Institution, Degree, and Year

University of New Hampshire, BA Art/Architecture History, 2005

Past 10 Years of Employment by Employer, Title and Time Period. List chronologically, beginning with most recent employment. Add more forms if space is needed for additional employment history entries.

Employer	Title	Time Period
Bay State Metal Finishing Corp.	President	2012-current
Woods Hole Oceanographic Institution	Engineer	2009-2012

Applicant Corporation Solar Therapeutics

Wolseley / Stock Building Supply	Manager in Training and Sales	Jan 2007 - 2009

Signed under the pains and penalties of perjury, I agree and attest that all information included in this form is complete and accurate.



Signature of the Individual

1/9/2018

Date Signed

SECTION D. EMPLOYMENT AND EDUCATION FORM

This Employment and Education form must be completed and signed by each of the following individuals: The applicant's Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, individual responsible for marijuana for medical use cultivation operations, and individual responsible for the RMD security plan and security operations. If the applicant does not have a Chief Executive Officer, Chief Operating Officer, or Chief Financial Officer, it must identify the individuals performing the equivalent duties for the Applicant and submit this form for each said individual. Submit one Employment and Education form for each of the above individuals when submitting a *Management and Operations Profile* to the Department of Public Health.

Name of Individual

Colleen Kanaley Dow

Residential Address of Individual**Title of Individual (at Applicant Corporation)**

Director of Cultivation

Name of Applicant Corporation

Solar Therapeutics

Highest Education Attained – Institution, Degree, and Year

Cape Cod Community College, Horticulture Certificate, 2008

Cape Cod Community College, Liberal Arts Concentration - Associate's Degree, 2007

Past 10 Years of Employment by Employer, Title and Time Period. List chronologically, beginning with most recent employment. Add more forms if space is needed for additional employment history entries.

Employer	Title	Time Period
Kanaley School of Irish Dance	Owner, TCRG. Irish Dancing Instructor	2011-present
Silver Lake Regional High School	Horticulture Teacher	2016-2017

Applicant Corporation **Solar Therapeutics**

Town of Bourne - Bourne Police Department	Dispatch	2012-2016
Artistic Garden Design	Gardner	2012-2016
Macy's Department Store	Seasonal Sales	2015-2016
Loon Mountain - Boyne Resorts	Seasonal Instructor	2012-2016

Signed under the pains and penalties of perjury, I agree and attest that all information included in this form is complete and accurate.


Signature of the Individual


Date Signed

SECTION D. EMPLOYMENT AND EDUCATION FORM

This Employment and Education form must be completed and signed by each of the following individuals: The applicant's Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, individual responsible for marijuana for medical use cultivation operations, and individual responsible for the RMD security plan and security operations. If the applicant does not have a Chief Executive Officer, Chief Operating Officer, or Chief Financial Officer, it must identify the individuals performing the equivalent duties for the Applicant and submit this form for each said individual. Submit one Employment and Education form for each of the above individuals when submitting a *Management and Operations Profile* to the Department of Public Health.

Name of Individual

Colleen Kanaley Dow

Residential Address of Individual**Title of Individual (at Applicant Corporation)**

Director of Cultivation

Name of Applicant Corporation

Solar Therapeutics

Highest Education Attained – Institution, Degree, and Year

Cape Cod Community College, Horticulture Certificate, 2008

Cape Cod Community College, Liberal Arts Concentration - Associate's Degree, 2007

Past 10 Years of Employment by Employer, Title and Time Period. List chronologically, beginning with most recent employment. Add more forms if space is needed for additional employment history entries.

Employer	Title	Time Period
Upper Cape Cod Regional Technical High School	Horticulture Teacher	2009-2010
Chris Mark and Sons Landscaping	Foreman	2007-2012

Courtney's Floral Creations	Manager	2003-2009

Signed under the pains and penalties of perjury, I agree and attest that all information included in this form is complete and accurate.

Calleen Haley Faden
Signature of the Individual

1/11/18
Date Signed

Applicant Corporation Solar Therapeutics

SECTION D. EMPLOYMENT AND EDUCATION FORM

This Employment and Education form must be completed and signed by each of the following individuals: The applicant's Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, individual responsible for marijuana for medical use cultivation operations, and individual responsible for the RMD security plan and security operations. If the applicant does not have a Chief Executive Officer, Chief Operating Officer, or Chief Financial Officer, it must identify the individuals performing the equivalent duties for the Applicant and submit this form for each said individual. Submit one Employment and Education form for each of the above individuals when submitting a *Management and Operations Profile* to the Department of Public Health.

Name of Individual

Kevin P. Traver

Residential Address of Individual

Title of Individual (at Applicant Corporation)

Director of Security

Name of Applicant Corporation

Solar Therapeutics

Highest Education Attained – Institution, Degree, and Year

Bradford College - Bachelor of Arts, Creative Arts - 2000


Past 10 Years of Employment by Employer, Title and Time Period. List chronologically, beginning with most recent employment. Add more forms if space is needed for additional employment history entries.

Employer	Title	Time Period
Entergy Nuclear Operations, Inc. - Pilgrim Nuclear Power Station	Security Training Supervisor	12/2015 - Current
Entergy Nuclear Operations, Inc. - Pilgrim Nuclear Power Station	Sr. Security Training Supervisor	01/2014 - 12/2015

Applicant Corporation Solar Therapeutics

Entergy Nuclear Operations, Inc. - Pilgrim Nuclear Power Station	Security Training Supervisor	01/2007 - 06/2009
Entergy Nuclear Operations, Inc. - Pilgrim Nuclear Power Station	Security Shift Supervisor	01/2007 - 06/2009

Signed under the pains and penalties of perjury, I agree and attest that all information included in this form is complete and accurate.


Signature of the Individual

01/09/2018
Date Signed